Complete Gut Health Solutions One Ecosystem. Seven Science-Led Strategies

Gut health is no longer defined by a single microorganism or digestive benefit. The modern view is more connected: targeted solutions can address food breakdown, microbial ecology, fermentation, digestive comfort and intestinal-barrier biology. Sabinsa’s Complete Gut Health Solutions portfolio brings these complementary approaches together through seven branded ingredients LactoSpore®, DigeZyme®, LactoCran®, LactoWise®, Starmeric®, ImmunoSpore® and PoZibio®-creating a versatile platform for premium supplements, functional foods and personalized wellness concepts.

At the foundation is LactoSpore®, the spore-forming probiotic strain Heyndrickxia coagulans MTCC 5856, historically published as Bacillus coagulans and Weizmannia coagulans MTCC 5856(1–3). Its spore-forming biology supports stability and formulation versatility. Strain-level identification matters because probiotic characteristics and clinical outcomes cannot automatically be extrapolated across strains.

Human studies reinforce LactoSpore® digestive-health positioning. In a multicentre, randomized, double-blind, placebo-controlled trial, 70 adults with functional gas and bloating received 2 billion spores daily or placebo for four weeks. MTCC 5856 produced significantly greater improvements in gastrointestinal symptom scores and global patient evaluation, and was well tolerated (4). A separate 28-day randomized study in 30 healthy adults found that the same daily intake maintained normal digestive- and general-health parameters, with minimal overall microbiome changes and no reported adverse events (5).

In a randomized pilot study involving adults with diarrhoea-predominant irritable bowel syndrome receiving protocol-defined standard care, adjunctive MTCC 5856 improved abdominal pain, bloating, diarrhoea, stool frequency and quality-of-life measures versus placebo (6).

DigeZyme® complements the microbiome story at the beginning of the digestive journey. The non-animal-derived multi-enzyme complex combines alpha-amylase, neutral protease, lipase, cellulase and lactase-enzymes selected to act on carbohydrates, proteins, fats, cellulose and lactose. In a randomized, double-blind, placebo-controlled trial of 40 adults with functional dyspepsia, 50 mg three times daily for 60 days produced significantly greater improvements than placebo across validated symptom and quality-of-life measures; no product-related adverse events were reported (7). The portfolio then moves from digestion to microbial nutrition. LactoCran® combines LactoSpore with cranberry seed fibre. In-vitro research found that the fibre resisted simulated gastric and pancreatic digestion, supported MTCC 5856 growth and was fermented with short-chain-fatty-acid production, providing a product-relevant scientific rationale for the combination (8). This creates a differentiated formulation story connecting a characterized probiotic strain with a complementary plant-derived fibre.

LactoWise® pairs LactoSpore® with Fenumannans®, a galactomannan-rich soluble fibre from fenugreek. Published laboratory research showed that fenugreek galactomannan resisted simulated upper-gastrointestinal digestion, was utilized by MTCC 5856 and supported short-chain-fatty-acid production during fermentation (9). These findings establish a mechanistic basis for combining the strain and substrate in a synbiotic concept. Product-level synbiotic health benefits ultimately require demonstration in the host, in accordance with the ISAPP consensus definition (10).

Starmeric® expands the microbial-nutrition strategy through insoluble turmeric fibre containing resistant starch. Resistant starch can escape small-intestinal digestion and become available for microbial fermentation in the colon, producing metabolites that can include acetate, propionate and butyrate (11). Its scientifically appropriate positioning is as a resistant-starch ingredient offering fermentable-substrate potential and broad formulation flexibility.

ImmunoSpore® adds a second, strain-specific postbiotic strategy. It is a heat-inactivated preparation of Heyndrickxia coagulans MTCC 5856-the same characterized strain used in LactoSpore-designed for applications in which a non-viable microbial format offers formulation advantages. In a randomized, investigator- and participant-blinded, placebo-controlled study, 60 healthy adults aged 18–49 years received ImmunoSpore at 150 mg daily or placebo for 30 days. No adverse events or clinically significant changes in vital signs or laboratory parameters were reported, supporting its safety as a dietary-supplement ingredient (16).

PoZibio® brings a complementary postbiotic platform to the portfolio. ISAPP defines a postbiotic as a preparation of inanimate microorganisms and/or their components that confers a health benefit on the host (12) PoZibio® contains heat-inactivated Lacticaseibacillus paracasei D3-5, historically published as Lactobacillus paracasei D3-5(13). Preclinical research linked heat-killed D3-5 and its cell-wall lipoteichoic acid with intestinal-barrier and inflammatory pathways in ageing models.[14] In a 30-day open-label pilot involving 13 adults aged 50 years and above, PoZibio® was well tolerated and its intake was associated with improvements in gastrointestinal-symptom and emotional-wellbeing scores (15).

Together, the seven ingredients create a modular gut-health design system. DigeZyme® supports nutrient breakdown; LactoSpore® provides a clinically studied, shelf-stable probiotic; LactoCran® and LactoWise® connect microbial and fibre strategies; Starmeric® supplies resistant starch with fermentable-substrate potential; ImmunoSpore® extends MTCC 5856 into a heat-inactivated postbiotic format; and PoZibio® adds a postbiotic platform for healthy-ageing concepts. Formulators can select a targeted technology or build complementary concepts around digestive comfort, microbiome-focused nutrition, active lifestyles, healthy ageing or the gut–brain axis.

That is the portfolio’s defining strength. Complete gut health is approached through coordinated support across digestion, fermentation, microbial activity and barrier biology-translated into differentiated branded ingredients with formulation flexibility and a clear scientific narrative designed for contemporary global wellness innovation and versatile product development across modern consumer formats worldwide.

References and notes

1. List of Prokaryotic names with Standing in Nomenclature. Heyndrickxia coagulans. Accessed October 2026. https://lpsn.dsmz.de/species/heyndrickxia-coagulans
2. Liang J, et al. Progress of research and application of Heyndrickxia coagulans as probiotic bacteria. Front Cell Infect Microbiol. 2024;14:1415790. doi:10.3389/fcimb.2024.1415790.
3. Narsing Rao MP, et al. Genome-based reclassification supporting the genus Heyndrickxia. See LPSN taxonomic record.
4. Majeed M, et al. Effects of Bacillus coagulans MTCC 5856 on functional gas and bloating in adults. Medicine. 2023;102:e33109. doi:10.1097/MD.0000000000033109.
5. Majeed M, et al. Probiotic modulation of gut microbiota by Bacillus coagulans MTCC 5856 in healthy subjects. Medicine. 2023;102:e33751. doi:10.1097/MD.0000000000033751.
6. Majeed M, et al. Bacillus coagulans MTCC 5856 in diarrhoea-predominant irritable bowel syndrome. Nutr J. 2016;15:21. doi:10.1186/s12937-016-0140-6.
7. Majeed M, et al. Safety and efficacy of a multienzyme complex in functional dyspepsia. J Med Food. 2018;21:1120–1128. doi:10.1089/jmf.2017.4172.
8. Majeed M, et al. Cranberry seed fibre and fermentation by Bacillus coagulans MTCC 5856. Int J Food Sci Technol. 2018;53:1640–1647. doi:10.1111/ijfs.13747.
9. Majeed M, et al. Fenugreek galactomannan and fermentation by Bacillus coagulans MTCC 5856. Food Sci Nutr. 2018;6:666–673. doi:10.1002/fsn3.606.
10. Swanson KS, et al. ISAPP consensus statement on synbiotics. Nat Rev Gastroenterol Hepatol. 2020;17:687–701. doi:10.1038/s41575-020-0344-2.
11. Chen Z, et al. Resistant starch and the gut microbiome. Food Chem X. 2024;21:101118.
12. Salminen S, et al. ISAPP consensus statement on postbiotics. Nat Rev Gastroenterol Hepatol. 2021;18:649–667. doi:10.1038/s41575-021-00440-6.
13. Zheng J, et al. A taxonomic note on the genus Lactobacillus. Int J Syst Evol Microbiol. 2020;70:2782–2858. doi:10.1099/ijsem.0.004107.
14. Wang S, et al. Lipoteichoic acid from heat-killed Lactobacillus paracasei D3-5 and ageing-related gut barrier function. GeroScience. 2020;42:333–352.
15. Lloyd A, et al. Safety and effects of heat-inactivated Lactobacillus paracasei D3.5 in older adults. Innov Aging. 2024;8(Suppl 1):1273. doi:10.1093/geroni/igae098.4069.
16. Majeed A, et al. Safety of heat-inactivated Heyndrickxia coagulans MTCC 5856 (ImmunoSpore®) in healthy adults. Eur J Integr Med. 2026;85:102676. doi:10.1016/j.eujim.2026.102676.
17. Health claims are not approved by EFSA or FDA- and these products are not for cure and treat any diseases.

Disclaimer: Health claims are not approved by EFSA or FDA- and these products are not for cure and treat any diseases.

Contributed by: Dr. Umar Jan, PhD, MBA
President European Operations, Sabinsa Europe GmbH